SRNE

Sorrento Therapeutics, Inc.
SRNE

Overview Fund Trends Analyst Outlook Journalist POV
Delisted

SRNE was delisted on the 22nd of February, 2023.

Back to rankings
 

About: Sorrento Therapeutics Inc is a biotechnology company focused on the development of novel immunotherapies for oncology and autoimmune/inflammation diseases. The antibody technologies target various locations: extracellular, intracellular, and membrane-bound antigens. The product portfolio consists of BioSimilar/BioBetter antibodies, CAR-T programs for the treatment of solid tumors, adoptive cellular therapies, immuno-oncology mAbs, and antibody-drug conjugates.

Employees: 799

Price charts implemented using Lightweight Charts™